JY
CAPR icon

Jeff Yass’s Capricor Therapeutics CAPR Stock Holding History

Jeff Yass’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Buy
528,000
+268,100
+103% +$8.13M ﹤0.01% 3018
2026
Q1 		$7.9M Sell
259,900
-1,172,100
-82% -$31.2M ﹤0.01% 3480
2025
Q4 		$41.3M Buy
1,432,000
+816,100
+133% +$10.7M ﹤0.01% 1532
2025
Q3 		$4.44M Sell
615,900
-306,800
-33% -$2.26M ﹤0.01% 4267
2025
Q2 		$9.16M Buy
922,700
+744,500
+418% +$7.86M ﹤0.01% 2955
2025
Q1 		$1.69M Buy
178,200
+54,800
+44% +$761K ﹤0.01% 5918
2024
Q4 		$1.7M Buy
123,400
+1,600
+1% +$28K ﹤0.01% 5675
2024
Q3 		$1.85M Buy
121,800
+111,300
+1,060% +$551K ﹤0.01% 5417
2024
Q2 		$50.1K Sell
10,500
-17,400
-62% -$97K ﹤0.01% 11413
2024
Q1 		$189K Sell
27,900
-25,500
-48% -$123K ﹤0.01% 10648
2023
Q4 		$261K Sell
53,400
-6,700
-11% -$21.8K ﹤0.01% 10123
2023
Q3 		$206K Buy
60,100
+48,900
+437% +$275K ﹤0.01% 10170
2023
Q2 		$53.5K Sell
11,200
-5,200
-32% -$22.8K ﹤0.01% 11311
2023
Q1 		$69.2K Sell
16,400
-95,600
-85% -$412K ﹤0.01% 11533
2022
Q4 		$432K Sell
112,000
-40,300
-26% -$192K ﹤0.01% 8245
2022
Q3 		$914K Sell
152,300
-500
-0.3% -$2.56K ﹤0.01% 6865
2022
Q2 		$533K Sell
152,800
-21,700
-12% -$77K ﹤0.01% 8104
2022
Q1 		$599K Sell
174,500
-24,300
-12% -$95.9K ﹤0.01% 8498
2021
Q4 		$582K Sell
198,800
-107,600
-35% -$377K ﹤0.01% 8776
2021
Q3 		$1.23M Buy
306,400
+109,000
+55% +$496K ﹤0.01% 7012
2021
Q2 		$1.01M Sell
197,400
-10,600
-5% -$44.9K ﹤0.01% 7721
2021
Q1 		$973K Buy
208,000
+12,300
+6% +$70.8K ﹤0.01% 7813
2020
Q4 		$671K Sell
195,700
-86,500
-31% -$375K ﹤0.01% 7636
2020
Q3 		$1.48M Buy
282,200
+227,200
+413% +$1.32M ﹤0.01% 5203
2020
Q2 		$253K Buy
+55,000
New +$240K ﹤0.01% 8641

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jeff Yass's CAPR Position: Q2 2026 in Review

Jeff Yass reduced its Capricor Therapeutics (CAPR) stake by 82% in Q2 2026, selling an estimated $1.33M and leaving 9,462 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #11673.

Jeff Yass first reported a position in CAPR in Q4 2015 and has held it in 27 quarters since. The position peaked at $3.88M in Q4 2024. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Jeff Yass held 9,462 shares of Capricor Therapeutics worth $228K as of Q2 2026.
  • Jeff Yass sold 43,913 Capricor Therapeutics shares in Q2 2026, an estimated $1.33M.
  • Capricor Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11673 holding.
  • Jeff Yass first reported a position in Capricor Therapeutics in Q4 2015 and has held it in 27 quarters since.
  • Jeff Yass's Capricor Therapeutics position peaked at $3.88M in Q4 2024.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.